Bremelanotide

Bremelanotide, marketed under the brand name Vyleesi, is a melanocortin receptor agonist designed to enhance sexual desire, primarily in women diagnosed with hypoactive sexual desire disorder (HSDD). Melanocortin receptor agonists are compounds that activate specific receptors in the brain involved in regulating appetite, energy balance, and sexual behavior. In the case of bremelanotide, stimulation of these receptors helps trigger pathways linked to sexual motivation and arousal.

Unlike medications that target blood flow, such as PDE5 inhibitors, bremelanotide acts centrally in the brain by stimulating melanocortin receptors involved in sexual motivation and arousal. It is FDA-approved for use in premenopausal women who experience low sexual desire that causes significant personal distress. Though not formally approved for men, early research indicates that bremelanotide may also support erectile function and libido in male populations.

Bremelanotide is fast-acting, typically taking effect within 45 minutes to a few hours after administration. It is delivered via self-injection into the thigh or abdomen, used on an as-needed basis prior to anticipated sexual activity. This central mode of action makes it distinct from other treatments by promoting desire and responsiveness through neural pathways rather than through direct vascular changes.

When used in combination with other agents, bremelanotide may offer synergistic benefits. For instance, pairing it with apomorphine—a dopamine agonist—can further enhance sexual desire by simultaneously activating dopaminergic and melanocortin systems in the brain. Adding tadalafil supports the vascular component of arousal by improving blood flow, while oxytocin, known for its role in bonding and emotional intimacy, can deepen feelings of connection and satisfaction.

This multi-pronged strategy targets the neurological, hormonal, and vascular systems involved in sexual function. As a result, it may be especially beneficial for individuals dealing with HSDD, erectile dysfunction, or low libido. However, responses to treatment vary, and potential side effects—such as nausea from bremelanotide, headache from tadalafil, or low blood pressure from apomorphine—should be carefully considered when evaluating this approach.